From: Patient-derived breast tumor xenografts facilitating personalized cancer therapy
 | Visonneau et al. [1] | Beckhove et al. [18] | Bergamaschi et al. [24] | DeRose et al. [8] | Zhang et al. [9] | Kabos et al. [20] | Petrillo et al. [22] | ||
---|---|---|---|---|---|---|---|---|---|
Transplantation site | Subcutaneous | Orthotopic, thoracic mammary gland | Intramuscular hind leg, matrigel | Interscapular fatpad | Subcutaneous back pocket, matrigel | Orthotopic, cleared mammary fatpad | Orthotopic, cleared mammary fatpad | Orthotopic, abdominal fatpad, matrigel | Subcutaneous dorsal flank |
Additional immunosuppression | Etoposide | Etoposide | Irradiated versus non-irradiated | None | None | None | None | None | None |
Estradiol | None | Yes, 5 days before transplant | None | 1.7 mg/pellet; 900 pg/ml | Yes | Yes, low dose | Yes, silastic pellet | Yes, 0.36 mg pellet | |
Mouse strain | SCID | NOD/SCID, NSG | NOD/SCID | Swiss nude | SCID | NOD/SCID | SCID/Beige, NSG | NOD/SCID, NSG | NOD/SCID |
Initial take rate | Primary tumors 8/16 (50%) | Â | 93 versus 90% irradiated; versus non-irradiated | 6/30 (20%), TG2 | 18/49 (37%) | Â | 10/24 (42%) >TG1 | Â | |
Stable take rate | Two lines were serially passaged | Â | Not serially passaged | 12.5% total (25/200) [6]; 2.5% (8/213) luminal 25% non-luminal, TG3 [21] | 3/30 (10%), TG8 2/30 (7%) >TG10 | 12/49 (27%) | 27 lines representing individual patients >TG5 | Â | 5/20 (25%) |
Xenograft versus patient concordant histopathology | Yes, one exception | Â | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Engraftment correlation with tumor features | Take rate did not correlate with pathological diagnosis, grading, or ER/PR status | Progression correlated with negative hormone status, high proliferative index, grade III | TNBC and metastases higher; non-luminal higher take rate than luminal | Not statistical but two stable were invasive grade III ductal carcinoma | 8/12 stable grafts from metastatic pleural effusions or ascites | TNBC and grade III higher take rate | Non-luminal higher take rate than luminal; ER status and high tumor grade | Receptor subtype and pathological grade higher take rate | |
IHC subtypes represented | Â | 4 TN 2 HER2+ 2 ER+ | Â | 1 ER-/PR- (lost PR) 1 ER+/PR+ | 5 TN 2 HER2+ 2 ER+ - | 21 TN 3 HER2+ 3 ER+ | 1 TN 5 ER+ | 0/12 ER/PR+ 4/4 TN 1/4 HER2+ | |
Metastases | Â | Yes, 5/8 (62%) micro-metastases [19] | Rare, two in lymph nodes | 10 models lung metastases | Â | 9/10 (90%) | 13/27 (48%) micro-metastases | Â | Â |
Genetic stability across generations | Â | Â | Â | Yes, CGH and Affymetrix microarray | Â | Yes, Agilent and SNP microarray | Yes, genomic, transciptomic, proteomic | Â | Â |